12:03 PM EDT, 03/20/2024 (MT Newswires) -- LivaNova ( LIVN ) shares rose nearly 12% in recent Wednesday trading after the company said its clinical study evaluating the aura 6000 device for moderate to severe obstructive sleep apnea has a more than 97.5% chance of meeting its primary endpoint.

The company said it will conclude enrolment of patients earlier than expected given this positive predictive outcome.

LivaNova ( LIVN ) said the study's primary endpoint is a "statistically significantly higher" apnea-hypopnea index responder rate for subjects with device stimulation compared with the rate for subjects without stimulation after a seven-month follow-up.

The study assesses the safety and effectiveness of the aura6000 Hypoglossal Nerve Stimulator System in obstructive sleep apnea patients who have failed or are unwilling to use positive airway pressure treatment, according to the company.

Price: 56.32, Change: +5.97, Percent Change: +11.87